28-Feb-2022

Kazia Therapeutics recruits first keto patient to Phase II paxalisib study for treatment of glioblastoma

Kazia Therapeutics (ASX: KZA)has recruited its first patient into a Phase II study of investigational new drug paxalisib for the treatment of newly-diagnosed and recurrent glioblastoma.

14-Feb-2022

Kazia Therapeutics advances human trials for lead cancer drugs during December quarter

Oncology-focused and clinical stage biotechnology company Kazia Therapeutics (ASX: KZA) has reported strong progress on the development of its lead drug candidates during the three months to 31 December.

07-Feb-2022

Kazia Therapeutics To Present At BIO CEO Conference

Kazia Therapeutics Limited will be presenting at the BIO CEO Conference, to be held in person and virtually in New York, NY, from 14-17 February 2022. Kazia will be presenting in person on day one of the conference, Monday, 14 February. The presentation will provide an update on recent progress with Kazia's two clinical-stage oncology programs and will cover some of the important catalysts expected during 2022